Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03354637 · ClinicalTrials.gov registry record · Phase 2
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT03354637 is a Phase 2 study that was terminated before completion, run by Aclaris Therapeutics. The registered enrollment target is 129 participants.
The verdict
NCT03354637, a Phase 2 study, was terminated before completion, sponsored by Aclaris Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
Primary: • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: • To evaluate key clinical outcome assessments
Interventions
- DRUG Placebo
- DRUG ATI-50002 high dose
- DRUG ATI-50002 low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2019-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03354637
The ClinicalTrials.gov registry entry for NCT03354637 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03354637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03354637 about?
NCT03354637 is a clinical study titled "A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata". Primary: • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: • To evaluate key clinical outcome assessments
What is the current status of trial NCT03354637?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2017-11-29. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT03354637?
The interventions under investigation include: Placebo (DRUG), ATI-50002 high dose (DRUG), ATI-50002 low dose (DRUG).
Who is sponsoring clinical trial NCT03354637?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.